EVALUATION OF TREATMENT OUTCOMES WITH IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AT CAN THO HEMATOLOGY AND BLOOD TRANSFUSION HOSPITAL
Main Article Content
Abstract
Background: Imatinib is a tyrosine kinase inhibitor used in the management of chronic myeloid leukemia (CML) in Vietnam. However, there is currently a lack of research data on treatment outcomes with this drug in Can Tho. Objectives: To evaluate the clinical characteristics, laboratory findings, and treatment outcomes of patients with CML treated with Imatinib at Can Tho Hematology and Blood Transfusion Hospital. Materials and methods: A non-controlled interventional study was conducted on 34 CML patients diagnosed and treated at Can Tho Hematology and Blood Transfusion Hospital. Results: The male-to-female ratio was approximately 1.27, with a mean age of 51.74 ± 16.31 years, the majority being 40 years or older. Splenomegaly was the most common clinical manifestation, observed in 70.6% of patients, followed by hepatomegaly (55.9%), fatigue (50%), and fever (50%). Prior to treatment, the median leukocyte count was 79.61 (Q1-Q3: 20.95-164.83) G/L, while the mean hemoglobin and platelet levels were 10.46 ± 2.44 g/dL and 504.15 ± 280.34 G/L, respectively. After three months of imatinib therapy, hemoglobin levels increased to 11.54 ± 1.94 g/dL, while leukocyte and platelet counts decreased to 6.74 (4.82-8.21) G/L and 196.26 ± 96.17 G/L, respectively. These changes were statistically significant (p < 0.05). The overall response rate was 82.4%. Conclusion: After three months of imatinib therapy, the majority of CML patients demonstrated significant improvements in peripheral blood parameters.
Article Details
Keywords
chronic myeloid leukemia (CML), treatment outcomes, imatinib
References


2. Hehlmann R., Berger U., Hochhaus A. Chronic myeloid leukemia: a model for oncology. Ann Hematol. 2005. 84(8), 487-97. doi:10.1007/ s00277-005-1039-z.


3. Kantarjian H. M., Jain N., Garcia-Manero G., Welch M. A., Ravandi F., et al. The cure of leukemia through the optimist's prism. Cancer. 2022. 128(2), 240-259. doi:10.1002/cncr.33933.


4. Bộ Y tế. Quyết định số 1832/QĐ-BYT về việc ban hành tài liệu chuyên môn Hướng dẫn chẩn đoán và điều trị một số bệnh lý huyết học. Bộ Y tế. 2022.

5. Phù Chí Dũng. Đánh giá hiệu quả của Nilotinib trên người bệnh bạch cầu mạn dòng tủy giai đoạn mạn đề kháng hoặc không dung nạp với Imatinib. Luận án tiến sỹ, Trường Đại học Y Hà Nội; 2020.

6. Sweet Kendra L., Al Ali Najla H., Lancet Jeffrey E., Creelan Ben, Tinsley Sara, et al. Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy. Blood. 2012. 120(21), 3740. doi:https://doi.org/10.1182/blood.V120.21. 3740.3740.


7. Hoffmann V. S., Baccarani M., Hasford J., Lindoerfer D., Burgstaller S., et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015. 29(6), 1336-43. doi:10.1038/leu.2015.73.


8. Suttorp M., Millot F., Sembill S., Deutsch H., Metzler M. Definition, Epidemiology, Pathophysiology, and Essential Criteria for Diagnosis of Pediatric Chronic Myeloid Leukemia. Cancers (Basel). 2021. 13(4), doi:10.3390/ cancers13040798.


9. Alsobhi Enaam Mohammed, Abrar Mohammed m, Abdelaal Mohammed A., Alsaeed Ahmad S., Al-Absi Ahmed, et al. Long Term Outcomes Of Imatinib In Chronic Myeloid Leukemia In Saudi Population, Single Center Study. Blood. 2013. 122(21), 5180-5180. doi:10.1182/blood.V122.21.5180.5180.

